ARTICLE | Company News
Geron, Merck deal
July 25, 2005 7:00 AM UTC
The companies will use GERN's telomerase technology with MRK's vaccine platform to develop a cancer vaccine targeting telomerase. GERN will receive an upfront payment and is eligible for milestones a...